Clinical TrialMay 15, 2026, 08:02 AM
CG Oncology's Bladder Cancer Drug Shows 96% EFS at 3 Months
AI Summary
CG Oncology announced positive first results from CORE‑008 Cohort CX, a Phase 2 study evaluating cretostimogene grenadenorepvec in combination with gemcitabine for high‑risk non‑muscle invasive bladder cancer. The study showed encouraging high-grade event-free survival (HG-EFS) of 96.0% at 3 months and 89.5% at 6 months. High complete response rates of 85.7% (ITT) and 92.3% (Efficacy Evaluable) were observed, along with a favorable safety profile with no Grade 3 or greater treatment-related adverse events.
Key Highlights
- High-grade event-free survival (HG-EFS) was 96.0% at 3 months in the ITT population.
- HG-EFS was 89.5% at 6 months in the overall intention-to-treat population.
- Complete response (CR) rate was 85.7% in the ITT CIS-containing population.
- CR rate was 92.3% in the Efficacy Evaluable CIS-containing population.
- No Grade 3 or greater treatment-related adverse events were reported.
- Efficacy was comparable across concurrent and sequential treatment arms.
- Median follow-up for the study was 6.6 months.
Price Impact
More from CGON